Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

FULC

Fulcrum Therapeutics Inc

Oct 04 • 04:00PM ET

3.82

Dollar change +0.15
Percentage change 4.23	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF IWM VTWO XPH IBB PINK IWN SCHA IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.35	Insider Own	15.49%	Shs Outstand	61.92M	Perf Week	1.33%
Market Cap	238.37M	Forward P/E	-	EPS next Y	-1.22	Insider Trans	-0.00%	Shs Float	52.73M	Perf Month	-55.74%
Income	-20.23M	PEG	-	EPS next Q	-0.40	Inst Own	82.06%	Short Float	21.62%	Perf Quarter	-36.86%
Sales	81.63M	P/S	2.92	EPS this Y	82.53%	Inst Trans	23.51%	Short Ratio	6.73	Perf Half Y	-55.16%
Book/sh	4.40	P/B	0.87	EPS next Y	-338.00%	ROA	-6.81%	Short Interest	11.40M	Perf Year	-1.80%
Cash/sh	4.39	P/C	0.87	EPS next 5Y	16.40%	ROE	-7.37%	52W Range	2.87 - 13.70	Perf YTD	-43.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.09%	ROI	-7.19%	52W High	-72.12%	Beta	2.21
Dividend TTM	-	Quick Ratio	22.07	Sales past 5Y	-1.10%	Gross Margin	97.69%	52W Low	33.33%	ATR (14)	0.55
Dividend Ex-Date	-	Current Ratio	22.07	EPS Y/Y TTM	81.75%	Oper. Margin	-40.15%	RSI (14)	35.95	Volatility	6.86% 10.64%
Employees	76	Debt/Eq	0.04	Sales Y/Y TTM	2582.55%	Profit Margin	-24.79%	Recom	2.62	Target Price	5.50
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	326.40%	Payout	-	Rel Volume	0.41	Prev Close	3.66
Sales Surprise	439.93%	EPS Surprise	311.17%	Sales Q/Q	8990.91%	Earnings	Jul 31 BMO	Avg Volume	1.69M	Price	3.82
SMA20	-15.44%	SMA50	-46.66%	SMA200	-51.14%	Trades		Volume	698,733	Change	4.23%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral	$17 → $4
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$15 → $4
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform	$4
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform	$10 → $2
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral	$5 → $10
May-20-24	Initiated	Cantor Fitzgerald	Overweight	$23
Mar-13-24	Initiated	RBC Capital Mkts	Outperform	$14
Sep-25-23	Initiated	Goldman	Neutral	$5
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$5 → $14
Aug-22-23	Upgrade	Stifel	Hold → Buy	$4 → $11
May-04-23	Downgrade	Goldman	Buy → Neutral	$9 → $3
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral	$20 → $6
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$11 → $8
Mar-09-23	Downgrade	Stifel	Buy → Hold	$35 → $6
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27 → $8
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy	$11
Mar-08-22	Initiated	Oppenheimer	Outperform	$33

Show Previous Ratings

Oct-04-24 09:35AM	Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround (Zacks)
Sep-17-24 01:30AM	RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares (GuruFocus.com) +9.75%
Sep-16-24 09:35AM	Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-13-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.56%
Sep-12-24 11:32AM	Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial (Benzinga) -61.13%
08:10AM	Loading…
08:10AM	Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test (BioPharma Dive)
06:55AM	Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) (GlobeNewswire)
Sep-09-24 02:28PM	Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease (Benzinga)
Aug-27-24 04:05PM	Fulcrum Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire) -9.09%
Aug-23-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.22%
Aug-21-24 09:55AM	Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade (Zacks)
Aug-19-24 07:00AM	Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer (GlobeNewswire)
Aug-09-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-24 12:00PM	Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -11.41%
12:00PM	Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know (Zacks)
09:55AM	Loading…
09:55AM	Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect? (Zacks)
Jul-31-24 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 (GlobeNewswire) +10.34%
Jul-24-24 08:00AM	Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET (GlobeNewswire)
Jun-12-24 08:00AM	Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress (GlobeNewswire)
Jun-06-24 08:00AM	Fulcrum Therapeutics to Participate in the Goldman Sachs' 45th Annual Global Healthcare Conference (GlobeNewswire)
May-26-24 09:02AM	Goldman Sachs Predicts up to 108% Rally for These 2 Strong Buy Stocks (TipRanks)
May-20-24 07:55AM	Cantor Fitzgerald Initiates Fulcrum Therapeutics at Overweight Rating With $23 Price Target (MT Newswires)
May-15-24 09:55AM	Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? (Zacks)
May-14-24 08:55AM	Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating (MT Newswires) +7.62%
07:49AM	Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 (MT Newswires)
03:01AM	Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
11:02AM	Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug (Pharmaceutical Technology)
08:45AM	Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment (MT Newswires)
08:32AM	Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ... (GuruFocus.com)
07:47AM	Loading…
07:47AM	Sanofi gambles $80M on Fulcrums muscular dystrophy drug (BioPharma Dive)
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 (GlobeNewswire)
06:00AM	Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy (GlobeNewswire)
May-09-24 08:00AM	Fulcrum Therapeutics to Participate in Upcoming May Conferences (GlobeNewswire)
May-08-24 08:00AM	Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology (GlobeNewswire)
May-06-24 08:00AM	Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET (GlobeNewswire)
Mar-28-24 04:05PM	Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
Mar-22-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-18-24 07:00AM	Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -10.92%
Mar-08-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-24 08:00AM	Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 09:35AM	Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 09:23PM	Q4 2023 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:10AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:35AM	Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023 (GlobeNewswire)
Feb-20-24 04:01PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET (GlobeNewswire)
Feb-06-24 08:00AM	Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-07-23 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.13%
Nov-10-23 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 08:00AM	Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences (GlobeNewswire) -18.71%
Nov-08-23 03:43PM	Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:03AM	Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com) +19.50%
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023 (GlobeNewswire)
Oct-31-23 08:50AM	Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET (GlobeNewswire) +8.66%
Sep-22-23 08:00AM	Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-15-23 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.07%
Sep-07-23 08:00AM	Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) (GlobeNewswire)
Aug-25-23 09:16AM	The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics (Zacks)
Aug-24-23 10:15AM	Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More (Zacks) -11.02%
08:42AM	Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate (Zacks)
01:35AM	4 big analyst picks: Nvidia racks up 3 new buy calls after blowout numbers (Investing.com)
Aug-22-23 02:02PM	Rebel's Edge - August 22: $M, $DKS, $FULC, and Jalen Carter (TheStreet.com) +38.52%
11:39AM	Fulcrum swings back up after FDA lifts clinical hold (American City Business Journals)
07:00AM	FDA Lifts Clinical Hold on Fulcrum Therapeutics FTX-6058 for Sickle Cell Disease (GlobeNewswire)
Aug-11-23 04:53PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-03-23 08:15AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023 (GlobeNewswire)
06:55AM	Fulcrum Therapeutics Appoints Chief Financial Officer (GlobeNewswire)
Jul-27-23 07:00AM	Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET (GlobeNewswire)
Jul-10-23 07:00AM	Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology (GlobeNewswire)
Jul-07-23 05:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.64%
Jun-20-23 07:00AM	Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) (GlobeNewswire) +6.00%
Jun-09-23 04:54PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-23 06:07AM	Fulcrum Therapeutics First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-15-23 11:37PM	Q1 2023 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +11.31%
08:15AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:05AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023 (GlobeNewswire)
07:00AM	Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer (GlobeNewswire)
May-08-23 04:05PM	Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET (GlobeNewswire) +8.64% +6.17%
May-05-23 06:06PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-23 01:01PM	Is Fulcrum Therapeutics (NASDAQ:FULC) In A Good Position To Invest In Growth? (Simply Wall St.)
Apr-07-23 05:00PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-05-23 08:00AM	Fulcrum Therapeutics Announces CFO Resignation (GlobeNewswire) -7.63%
Mar-10-23 05:00PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.43%
Mar-09-23 10:06PM	Q4 2022 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -23.00%
08:15AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022 (GlobeNewswire)
Mar-07-23 06:06AM	Investors in Fulcrum Therapeutics (NASDAQ:FULC) have unfortunately lost 61% over the last year (Simply Wall St.) +6.03%
Mar-06-23 04:05PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET (GlobeNewswire)
Feb-28-23 10:00AM	Analysts Estimate Bionano Genomics, Inc. (BNGO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-24-23 12:52PM	Shares of drugmaker Fulcrum pivot down as FDA temporarily halts trial (American City Business Journals) -56.09%
08:00AM	Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease (GlobeNewswire)
Feb-23-23 10:00AM	Fulcrum Therapeutics, Inc. (FULC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-16-23 09:55AM	Wall Street Analysts Think Fulcrum Therapeutics, Inc. (FULC) Could Surge 71.81%: Read This Before Placing a Bet (Zacks)
Feb-10-23 05:27PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-08-23 05:00PM	Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-01-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Fulcrum Therapeutics, Inc. (FULC) is a Great Choice (Zacks)
Jan-26-23 09:55AM	Wall Street Analysts Believe Fulcrum Therapeutics, Inc. (FULC) Could Rally 73.02%: Here's is How to Trade (Zacks)

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sapir Alex	See Remarks	Jul 03 '24	Option Exercise	3.27	150,000	490,500	193,360	Jul 08 08:00 AM
Tourangeau Greg	Principal Accounting Officer	May 07 '24	Sale	7.76	236	1,831	11,571	May 09 04:10 PM
Tourangeau Greg	Vice President, Finance	Mar 08 '24	Sale	11.72	4,884	57,219	11,807	Mar 08 06:05 PM
Sapir Alex	See Remarks	Mar 04 '24	Buy	11.35	43,360	492,028	43,360	Mar 05 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FULC

Fulcrum Therapeutics Inc

Upgrade your FINVIZ experience